Press release
Hyperglycemia Clinical Market to Reach USD 24.9 Billion by 2030
Hyperglycemia Clinical
The market includes diagnostics, CGM devices, insulin delivery systems, emergency care drugs, hospital-based monitoring tools, and clinical management services that help prevent complications such as diabetic (DKA), hyperosmolar hyperglycemic state (HHS), cardiovascular issues, and organ damage.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73636
Key Takeaways
• Market Size 2023: USD 14.5 billion
• Market Size 2030: USD 24.9 billion
• CAGR (2024-2030): 8.6%
• Largest Segment: Continuous glucose monitoring & insulin delivery technologies
• Fastest-Growing Segment: AI-enabled diabetic management & hospital hyperglycemia monitoring systems
Market Story
Hyperglycemia affects millions of patients globally-driven by Type 1 diabetes, Type 2 diabetes, gestational diabetes, stress-induced hyperglycemia, and drug-associated glucose elevation. Unmanaged hyperglycemia is a critical risk factor for cardiovascular events, renal failure, neuropathy, and emergency hospitalizations.
Clinical management has evolved from manual glucose checks to real-time, automated, connected, and predictive digital health ecosystems.
Key drivers boosting global market growth include:
• Higher diabetes incidence due to sedentary lifestyles, urbanization, aging populations, and obesity
• Wider adoption of continuous glucose monitoring (CGM)
• AI-powered predictive analytics improving glucose control
• Smart insulin pumps & closed-loop systems enabling near-automated glycemic control
• Hospital-based hyperglycemia protocols for inpatients and ICU settings
• Improved diagnostic access for early detection of glucose abnormalities
Governments, hospitals, and manufacturers are collaborating to reduce hyperglycemia-related complications and healthcare costs.
Market Segments
By Product Type
• Continuous Glucose Monitoring (CGM) Systems - Largest Segment
- Real-time CGM (rtCGM)
- Intermittently scanned CGM (isCGM)
• Insulin Delivery Systems
- Smart insulin pens
- Insulin pumps & patch pumps
- Closed-loop & hybrid automated insulin delivery
• Blood Glucose Testing Devices
- Glucometers
- Test strips & lancets
• Hyperglycemia Treatment Drugs
- Insulin
- Metformin
- SGLT2 inhibitors
- GLP-1 receptor agonists
- Rapid-acting agents for acute cases
• Emergency Care Products
- IV fluids
- Electrolyte solutions
- Rapid insulin infusion protocols
• Digital & AI-Based Platforms
- Connected diabetes management apps
- Telehealth glucose coaching
- Decision-support algorithms
CGM and insulin pumps dominate due to accuracy, convenience, and improved clinical outcomes.
By Application
• Type 2 Diabetes (Largest Application)
• Type 1 Diabetes
• Gestational Hyperglycemia
• Stress-Induced & Hospital Hyperglycemia
• Drug-Induced Hyperglycemia (e.g., Steroids, Immunotherapy)
• Acute Emergencies:
- DKA (Diabetic )
- HHS (Hyperosmolar Hyperglycemic State)
Hospital hyperglycemia is one of the fastest-growing clinical focus areas.
By End User
• Hospitals & Critical Care Centers (Largest End User)
• Diagnostic Laboratories
• Specialty Diabetes Clinics
• Home Healthcare Users
• Telehealth & Remote Monitoring Providers
Inpatients require continuous monitoring to avoid complications and improve recovery metrics.
Explore Full Report here: https://exactitudeconsultancy.com/reports/73636/hyperglycemia-clinical-market
Recent Industry Developments
• 2024 - Dexcom launched next-generation CGM with enhanced accuracy for inpatient & outpatient care.
• 2023 - Abbott expanded global rollout of FreeStyle Libre systems with improved insulin dosing support.
• 2023 - Medtronic introduced newer hybrid closed-loop insulin pump systems.
• 2023 - Eli Lilly advanced development of ultra-rapid insulin formulations for emergency glucose control.
• 2023 - Roche enhanced digital diabetes analytics platforms for hyperglycemia trend prediction.
Expert Quote
"Hyperglycemia management is entering a new era of predictive, connected, and automated care. Continuous monitoring and smart insulin technologies are fundamentally transforming patient outcomes."
- Irfan Tamboli, Business Development Executive, Exactitude Consultancy
Key Market Drivers
1. Rising Global Diabetes Prevalence
Over 530 million adults worldwide live with diabetes, with cases projected to rise sharply.
2. Shift to Real-Time Continuous Glucose Monitoring
CGM systems are replacing traditional finger-stick monitoring.
3. Hospital Hyperglycemia Protocol Adoption
Inpatient glucose control lowers complications and improves ICU outcomes.
4. AI-Driven Treatment Decisions
Predictive models and closed-loop systems reduce hypoglycemia and hyperglycemia events.
5. Increasing Use of Connected Insulin Delivery Systems
Smart pumps and pens improve adherence and reduce treatment errors.
Forecast Outlook (2024-2030)
Future advancements include:
• Fully autonomous closed-loop glucose control systems
• AI-powered hyperglycemia prediction tools
• Integration of wearable biosensors for multi-parameter monitoring
• Smart hospital wards with continuous wireless glucose tracking
• Expanded telehealth adoption for chronic hyperglycemia management
By 2030, hyperglycemia care will move toward precision, automation, and continuous remote monitoring.
Regional Insights
North America
Largest market due to early adoption of CGM, advanced insulin pumps, and strong clinical guidelines.
Europe
Growing reimbursement for CGM and hospital-based glycemic control systems.
Asia-Pacific (Fastest Growing Region)
Rapid rise in diabetes cases across India, China, Indonesia, and Japan.
Middle East & Latin America
Increasing investment in diabetes clinics and improved access to hyperglycemia diagnostics.
Conclusion
The Hyperglycemia Clinical Market is poised for strong growth as healthcare systems adopt continuous monitoring, intelligent insulin delivery, and advanced clinical protocols. With rising global diabetes prevalence, hyperglycemia management will remain a top priority for public health and hospital systems worldwide.
This report is also available in the following languages : Japanese (高血糖臨床市場), Korean (고혈당증 임상 시장), Chinese (高血糖临床市场), French (Marché clinique de l'hyperglycémie), German (Klinischer Markt für Hyperglykämie), and Italian (Mercato clinico dell'iperglicemia), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/73636
Related Reports
Sleep Apnea Clinical Market
https://exactitudeconsultancy.com/reports/73637/sleep-apnea-clinical-market
Amyotrophic Lateral Sclerosis Clinical Market
https://exactitudeconsultancy.com/reports/73649/amyotrophic-lateral-sclerosis-clinical-market
Pulmonary Tuberculosis Clinical Market
https://exactitudeconsultancy.com/reports/73650/pulmonary-tuberculosis-clinical-market
Acquired Autoimmune Hemolytic Anemia Clinical Market
https://exactitudeconsultancy.com/reports/73651/acquired-autoimmune-hemolytic-anemia-clinical-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hyperglycemia Clinical Market to Reach USD 24.9 Billion by 2030 here
News-ID: 4293215 • Views: …
More Releases from Exactitude Consultancy
Amyloidosis Clinical Market to Reach USD 8.3 Billion by 2030
The Global Amyloidosis Clinical Market is entering a significant growth phase driven by rapid adoption of targeted therapies, increased diagnostic capabilities, and expanding clinical research focused on subtypes like AL, ATTR, AA, and hereditary amyloidosis. According to Exactitude Consultancy, the market is projected to grow from USD 4.8 billion in 2023 to USD 8.3 billion by 2030, reflecting a CAGR of 7.9%.
Amyloidosis is a complex and often underdiagnosed condition involving…
Gaucher Disease Clinical Market to Reach USD 2.9 Billion by 2030
The Global Gaucher Disease Clinical Market is expanding steadily as advancements in enzyme replacement therapy (ERT), substrate reduction therapy (SRT), and gene therapy significantly improve outcomes for patients with this inherited lysosomal storage disorder. According to Exactitude Consultancy, the market is expected to grow from USD 1.8 billion in 2023 to USD 2.9 billion by 2030, achieving a CAGR of 6.5%.
The market encompasses diagnostics, drug therapies, patient monitoring, newborn screening…
Idiopathic Pulmonary Fibrosis (IPF) Clinical Market to Reach USD 6.2 Billion by …
The Global Idiopathic Pulmonary Fibrosis (IPF) Clinical Market is growing steadily as healthcare systems address the increasing burden of this chronic, progressive lung disease characterized by irreversible scarring of lung tissue. According to Exactitude Consultancy, the market is projected to rise from USD 3.8 billion in 2023 to USD 6.2 billion by 2030, registering a CAGR of 7.4%.
The market includes diagnostic tools, anti-fibrotic drugs, supportive care therapies, pulmonary rehabilitation, oxygen…
Dengue Fever Clinical Market to Reach USD 6.4 Billion by 2030
The Global Dengue Fever Clinical Market is accelerating as healthcare systems worldwide face rising dengue infection rates driven by climate change, rapid urbanization, and expanding mosquito habitats. According to Exactitude Consultancy, the market is projected to grow from USD 3.2 billion in 2023 to USD 6.4 billion by 2030, at a strong CAGR of 9.8%.
The market includes diagnostics, treatment, vaccines, supportive care, surveillance systems, and clinical management services-playing a crucial…
More Releases for Hyperglycemia
Exploring the Future of Hyperglycemia Treatment Market Set to Strategic Business …
Worldwide Market Reports has recently released a comprehensive research study titled "Hyperglycemia Treatment Market Size and Forecast 2025-2032: Breakdown by Manufacturers, Key Regions, Types, and Applications." The report has been developed using a combination of primary and secondary research methodologies, ensuring a detailed and accurate analysis. Drawing insights from both historical data and future projections, the study highlights the expected growth of the Hyperglycemia Treatment market in terms of both…
Hyperglycemia Clinical Market to Surpass $27.8 Billion by 2034, Exhibiting a 7.9 …
Introduction
Hyperglycemia-characterized by high blood glucose levels-is one of the most significant and growing global health challenges, often linked to diabetes, stress, and critical illness. While traditionally viewed as a symptom of diabetes, emerging medical research and improved diagnostics are redefining hyperglycemia as an independent clinical condition requiring specialized management. Increasing awareness, early detection programs, and technological advancements in glucose monitoring and insulin management systems have made hyperglycemia a priority in…
Hyperglycemia Market Massive Growth opportunity Ahead
Introduction
Hyperglycemia, or high blood glucose, is a common and serious condition associated with diabetes mellitus and other metabolic disorders. It is not only a key diagnostic marker of diabetes but also a major contributor to severe complications, including cardiovascular disease, kidney failure, and neuropathy. The global burden of diabetes continues to rise sharply, creating an urgent need for effective hyperglycemia management solutions.
As lifestyle changes, urbanization, and aging populations accelerate the…
Emerging Trends in Hyperglycemia Treatment Market 2032: New Study Forecasts Key …
"
The Hyperglycemia Treatment Market is experiencing significant growth, driven by the escalating prevalence of diabetes and related conditions worldwide. This market plays a crucial role in addressing the global health challenge posed by hyperglycemia, a condition characterized by elevated blood sugar levels. Key drivers for growth include advancements in insulin therapies, the development of novel oral hypoglycemic agents, and increasing awareness among healthcare professionals and patients regarding the importance of…
Global Hyperglycemia Treatment Market Poised for Robust Growth to reach USD 1,92 …
The global hyperglycemia treatment market is witnessing a remarkable surge in growth, driven by the increasing prevalence of diabetes and the growing number of patients experiencing hyperglycemia episodes. Hyperglycemia, characterized by elevated blood glucose levels, demands prompt and effective intervention to avoid severe health complications, including cardiovascular diseases, kidney damage, and nerve damage. With an ever-growing diabetic population and heightened awareness of diabetes management, the demand for advanced treatment options…
Hyperglycemia Treatment Market: The Report Analysis And Overview of Global Marke …
A Hyperglycemia Treatment Market 2023 Often, a research report includes a detailed examination of a certain market or industry.
Global Hyperglycemia Treatment Market 2023 is expected to experience robust growth, offering market players a profitable opportunity to expand their presence in acknowledging economies and increase their revenue streams. To strengthen their position and enhance their market share, companies can leverage this growth potential. To conduct a thorough analysis of the global…
